2024
Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis
Ilagan-Ying Y, Gordon K, Tate J, Lim J, Torgersen J, Re V, Justice A, Taddei T. Risk Score for Hepatocellular Cancer in Adults Without Viral Hepatitis or Cirrhosis. JAMA Network Open 2024, 7: e2443608. PMID: 39504020, PMCID: PMC11541635, DOI: 10.1001/jamanetworkopen.2024.43608.Peer-Reviewed Original ResearchConceptsClassification of DiseasesBody mass indexRisk scoreNinth Revision and International Statistical Classification of DiseasesMass indexAlcohol useInternational Statistical Classification of DiseasesStatistical Classification of DiseasesElectronic health recordsNon-Hispanic blacksInternational Classification of DiseasesNon-Hispanic whitesClinical Modification diagnosisHepatocellular carcinoma risk scoreRisk of hepatocellular carcinomaCox proportional hazards regression modelsValidation sampleHigh-risk individualsProportional hazards regression modelsHCC risk factorsFIB-4Multivariate risk scoreHepatocellular carcinomaHazards regression modelsViral hepatitis
2020
Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network
Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology 2020, 72: 1169-1176. PMID: 32725890, PMCID: PMC9258788, DOI: 10.1002/hep.31487.Peer-Reviewed Original ResearchConceptsAbnormal liver testsLiver testsCohort studyClinical outcomesCOVID-19Yale New Haven Health SystemCoronavirus-19 disease (COVID-19) pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virusRetrospective observational cohort studyAcute respiratory distress syndromeRetrospective cohort studyLiver test abnormalitiesObservational cohort studySevere COVID-19Liver transaminase elevationsRespiratory distress syndromeBody mass indexPoor clinical outcomeCoronavirus 2 virusCOVID-19 treatmentNonpulmonary manifestationsPeak hospitalizationsICU admissionMultiorgan failureTransaminase elevation
2018
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis
Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z, Group H. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology And Hepatology 2018, 16: 1811-1819.e4. PMID: 29306043, PMCID: PMC6034985, DOI: 10.1016/j.cgh.2017.12.037.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsBenzimidazolesDrug Therapy, CombinationDrug-Related Side Effects and Adverse ReactionsEuropeFemaleFluorenesGenotypeHepacivirusHepatitis C, ChronicHumansLiver CirrhosisLongitudinal StudiesMaleMiddle AgedNorth AmericaProspective StudiesRibavirinSofosbuvirSustained Virologic ResponseTreatment OutcomeYoung AdultConceptsTreatment-experienced patientsGenotype 1 HCV infectionAddition of ribavirinHCV infectionGenotype 1 hepatitis C virus infectionChronic genotype 1 HCV infectionHepatitis C virus infectionHCV-TARGET studyRate of SVR12Treatment-experienced adultsC virus infectionPrimary efficacy endpointGenotype 1 infectionObservational cohort studyWeeks of treatmentEnd of treatmentRoutine clinical practiceSofosbuvir treatmentVirologic outcomesVirologic responseEfficacy endpointHepatitis CProtocol populationAdverse eventsCohort study
2017
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease
Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2017, 46: 1061-1069. PMID: 28960360, DOI: 10.1111/apt.14342.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseFatty liver diseaseLarger tumor sizeLiver diseaseHCC etiologyCurative intentNAFLD-HCCCurative treatmentTumor sizeMetastatic HCCCardiovascular diseaseHepatocellular carcinomaDecompensated liver diseaseWorse median survivalAbsence of cirrhosisSignificant survival differenceDiagnosis of HCCLess cirrhosisNAFLD groupMedian survivalWorse survivalFavorable survivalIndependent predictorsLiver cirrhosisHCC group
2015
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study. Alimentary Pharmacology & Therapeutics 2015, 43: 134-144. PMID: 26510638, PMCID: PMC4926997, DOI: 10.1111/apt.13440.Peer-Reviewed Original ResearchConceptsALT normalisationAdverse eventsHBV DNAHBeAg(-) patientsHBV patientsTreatment-naïve chronic hepatitis B patientsChronic hepatitis B patientsFive-year cumulative probabilityHBsAg loss/seroconversionLog 10 IU/Hepatitis B virus infectionEffectiveness of entecavirMedian HBV DNAUndetectable HBV DNAHepatitis B patientsB virus infectionAbnormal ALTEntecavir treatmentETV treatmentHBeAg lossHBsAg lossHepatic decompensationB patientsCohort studyMedian duration